Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer

NCT05232175 | Completed Phase 1 Results

• 1 other identifier: ALT-BB4-01
• Study Type: interventional
• Target: 290
• Locations: 1 country
• Sites: 1

Brief Summary

A Phase I Study to Evaluate the Tolerance, Safety and Pharmacokinetics of ALT-BB4 in Healthy Volunteers

Conditions

Health, Subjective

Outcome Measures

Primary Outcomes (2)

• Incidence Rate of Drug Allergy Following ID Injection of the IP

  Subject developing either immediate or delayed allergic reaction are considered to have drug allergy.

  2 days

• Injection-site TEAEs (Treatment Emergent Adverse Events)

  Incident rate of administration site-related adverse events in Part Ⅱ-B

  4 weeks

Study Arms (5)

Part I (Allergy assessment) - ALT-BB4

EXPERIMENTAL

Drug: ALT-BB4

Part I (Allergy assessment) - 0.9%NaCl

PLACEBO COMPARATOR

Drug: 0.9%NaCl

Part II-A (PK assessment)

EXPERIMENTAL

Drug: ALT-BB4

Part II-B (Safety assessment) - ALT-BB4

EXPERIMENTAL

Drug: ALT-BB4

Part II-B (Safety assessment) - 0.9% NaCl

PLACEBO COMPARATOR

Drug: 0.9%NaCl

Interventions

ALT-BB4 DRUG

Recombinant Hyaluronidase

Part I (Allergy assessment) - ALT-BB4; Part II-A (PK assessment); Part II-B (Safety assessment) - ALT-BB4

0.9%NaCl DRUG

Normal Saline

Part I (Allergy assessment) - 0.9%NaCl; Part II-B (Safety assessment) - 0.9% NaCl

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Common
• Healthy volunteers aged ≥19 years at the time of Screening (Visit 1)
• Female subjects or male subjects' female partner must be menopausal or should have received a sterilization procedure or have agreed to use contraceptive methods during the study period, as defined below:
• Post-menopausal female subjects or male subjects' female partners (non-drug induced amenorrhea for at least 12 months or confirmed diagnosis with menopause)
• Female subjects or male subjects' female partners who have received a sterilization procedure (removal of ovary and/or uterus)
• Subjects who have agreed to practice total abstinence during the study period \[For female subjects, periodic abstinence (e.g., ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.\]
• When female subjects or male subjects' female partners are women of childbearing potential (WOCBP) who have not received a sterilization procedure, they must agree to use of following contraceptive methods:
• Hormones (implantable, patch, and oral)
• Intrauterine device (IUD)
• Double barrier methods (concomitant use of two of following contraceptive methods: male condom, female condom, cervical cap, diaphragm, sponge, spermicide) (However, concomitant use of male condom and female condom is excluded from double barrier methods.)
• WOCBP or females who have the last menstrual period within 12 months must have a negative serum or urine pregnancy test at Screening (Visit 1).
• Subjects who have voluntarily decided to take part in the study and able to comply with the study protocol
• Subjects who have no tattoo, acne, dermatitis, pigmentation or lesion on the administration site and who have no damage in the skin, so that they can receive the IP and allergy test
• Subjects determined eligible for the study through Screening tests (vital signs, physical examination, medical history and surgery history, ECG, and laboratory tests)
• Part II-A

You may not qualify if:

• Common
• Subjects who have received or treated with following medications within the specified timeframe prior to Screening (Visit 1) or who are expected to receive them during the study period:
• Within 1 month: Hyaluronidase, Chemotherapeutic agent, non-steroidal anti-inflammatory drugs (NSAIDs; e.g.: Aspirin, Aceclofenac, etc.), penicillins antibiotics (e.g.: Amoxicillin, Ampicillin, etc.), cephalosporins antibiotics (e.g.: Cefaclor, Cefadroxil, Cefixime, etc.), sulfonamides antibiotics (e.g.: Sulfadiazine, Sulfamethoxazole, etc.), quinolones antibiotics (e.g.: Ciprofloxacin, Levofloxacin, etc.), Glucocorticosteroid, Immunosuppressive agent
• Within 14 days: Antihistamine (e.g.: Chlorpheniramine, Hydroxyzine, Ketotifen, etc.)
• Subjects who have prior history of clinically significant liver, kidney, nervous system, immune system, respiratory system, endocrine system, hematology/neoplasm, cardiovascular system, mental (mood disorder, obsessive-compulsive disorder), gastrointestinal disorders or surgical history
• Subjects with acute fever \> 37.5℃ within 7 days from the expected IP administration or showing symptoms suspecting acute diseases within 14 days from the expected IP administration
• Subjects who do not have normal blood pressure\*
• \*Range of normal blood pressure is defined as systolic and diastolic blood \<120/80 mmHg in accordance with 2018 Korean Society of Hypertension Guidelines for the Management of Hypertension24) (however, Pre-hypertension (≥ 130/80) is excluded that may occur in normotension).
• Subjects who persistently drink more than the weekly recommended alcohol units\* 14 g of alcohol content per unit is applied, which corresponds to 1 can (small bottle) of beer (5%), 350 mL of draft beer (5%), 1 cup (300 mL) of makgeoli, 1 glass (150 mL) of wine (12%), 1/4 bottle (90 mL) of soju (20%), and 1 shot (45 mL) of liquor (40%). Moderate amount of alcohol by age and gender is provided below:23) Age Recommended unit per week Adults (≥ 19 and \< 65 years) Male: 8 units/week Female: 4 units/week Elderly (≥ 65 years) Male: 4 units/week Female: 2 units/week
• Subjects of usual smoker (exceeding 10 cigarettes per day)
• Subjects who have a past history of autoimmune diseases (e.g.: rheumatoid arthritis, etc.) or active immune diseases that may affect the immune system \[e.g.: flu, cancer, Human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV) etc.\], diabetes mellitus, heart diseases, asthma, sinusitis, chronic urticaria, dermographism, or any skin conditions that may affect post-IP administration assessments (e.g.: Dermatitis, dermatomycosis and other skin diseases or tattoo)
• Subjects with known allergic reactions or hypersensitivity to bee sting or other common allergens or known contraindications to hyaluronidase, thimerosal (disinfectants) and EDTA
• Subjects with hypersensitivity to the IP or its ingredients or a history of anaphylaxis
• Past history of drug abuse
• Subjects who have participated in other clinical trials within 6 months prior to the expected IP administration

Sponsors & Collaborators

• Alteogen, Inc.: lead

Study Sites (1)

Research Site

Seoul, South Korea

Location

Related Publications (1)

• Lee JS, Kim W, Won CH, Lee YW, Lee S, Won H, Park SJ, Lee S, Kim SH, Yang J, Bahn G, Lee DH. The Safety, Tolerability, and Pharmacokinetics of ALT-BB4 (A Novel Recombinant Hyaluronidase): A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study in Healthy Volunteers. Dermatol Ther (Heidelb). 2025 Nov;15(11):3301-3311. doi: 10.1007/s13555-025-01507-x. Epub 2025 Sep 2.

  PMID: 40892310 DERIVED

MeSH Terms

Interventions

Sodium Chloride

Intervention Hierarchy (Ancestors)

Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Results Point of Contact

• Title: Alteogen Inc.
• Organization: Alteogen Inc.

med.info@alteogen.com

0000

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 14, 2022
• First Posted: February 9, 2022
• Study Start: January 18, 2022
• Primary Completion: August 24, 2022
• Study Completion: August 24, 2022
• Last Updated: January 29, 2026
• Results First Posted: January 29, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)